Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma..
Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population .

Start Date01 Oct 2022

Sponsor / Collaborator

Assiut University

NCT05854511 / RecruitingPhase 3IIT

Pharmacokinetics, Safety, Efficacy and Acceptability Study of Daclatasvir/Sofosbuvir in Children Weighing 14-35 Kilograms With Chronic Hepatitis C Virus Infection

This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection.

Start Date05 Jun 2022

Sponsor / Collaborator

Ain Shams University

[+1]

NCT05616598 / CompletedPhase 2/3IIT

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has been used in treatment of HCVs. the effect of these drugs on male infertility is still under investigation.

Start Date01 Mar 2022

Sponsor / Collaborator

Benha University

100 Clinical Results associated with Daclatasvir Dihydrochloride

100 Translational Medicine associated with Daclatasvir Dihydrochloride

100 Patents (Medical) associated with Daclatasvir Dihydrochloride

1,312

Literatures (Medical) associated with Daclatasvir Dihydrochloride

01 Dec 2024·Bioorganic Chemistry

Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing

Article

Author: Yu, Menglin ; Wang, Shisheng ; Lv, Shixuan ; Guo, Xiuhan ; Gao, Xinru ; Li, Yueqing ; Gao, Zhigang ; Sun, Mengmeng ; Song, Qiling ; Wang, Shuai ; Ma, Chunyan ; Zhang, Li ; Meng, Qingwei ; Pan, Yanyan

This study employed a drug repositioning strategy to discover novel PD-L1 small molecule inhibitors. 3D-QSAR pharmacophore models were establishedand subsequently validated through various means to select a robust model, Hypo-1, suitable for virtual screening. Hypo1 was used toscreen a library of 7,475 compounds from the Drugbank database, leading to the identification of 283 molecules following molecular docking with PD-L1.19 compounds underwent HTRF assays, with 15 showing varying degrees of inhibition of the PD-1/PD-L1 interaction. Compounds2202,2204,2207, and2208were further confirmed to bind to PD-L1 using SPR experiments. Among them, compound2204(Daclatasvir, K_D = 11.4 μM) showeda higher affinity for human PD-L1 than the control compound BMS-1. In the HepG2/Jurkat cell co-culture model, Daclatasvir effectively activated Jurkat cells to kill HepG2 cells. In the mouse H22 hepatocellular tumor model, Daclatasvir significantly inhibited tumor growth (TGI = 53.4 % at a dose of 100 mg/kg). Its anti-tumor effect was more pronounced when combined with Lenvatinib (TGI = 85.1 %). Flow cytometry analysis of splenocytes and tumor cells indicated that Daclatasvir activated the immune system in both models. In summary, Daclatasvir was identified as a novel PD-L1small molecule inhibitor.

01 Dec 2024·Carbohydrate Polymers

Molecular modeling study to unravel complexation of daclatasvir and its enantiomer by β-cyclodextrins. Computational analysis using quantum mechanics and molecular dynamics

Article

Author: Scriba, Gerhard K E ; Dessì, Alessandro ; Dallocchio, Roberto ; Scriba, Gerhard K.E. ; Chankvetadze, Bezhan ; Peluso, Paola ; Salgado, Antonio

A computational study was performed to unravel mechanisms underlying capillary electrophoresis enantioseparations of daclatasvir and its (R,R,R,R)-enantiomer with native and methylated β-cyclodextrins (β-CDs) as chiral selectors. Considering the enantioseparation results as benchmark, the structures of β-CD and seven methylated β-CDs were optimized by quantum mechanics, and their topography and computed molecular properties were compared. Furthermore, the electron charge density distribution of the macrocycles was also evaluated by calculating the molecular electrostatic potential of pivotal regions of native and methylated β-CDs. The function of hydrogen bonds in the complexation process of daclatasvir and the CDs was derived from quantum mechanics analysis and confirmed by molecular dynamics, as orthogonal computational techniques. The presence of a round-shaped cavity in the CDs used as chiral selector appeared as a necessary requirement for the enantioseparation of daclatasvir and its (R,R,R,R)-enantiomer. In this regard, it was confirmed that the round shape of the CDs is sustained by hydrogen bonds formed between adjacent glucopyranose units and blocking rotation of the linking glycosidic bonds. The presence of hydroxy groups at the 6-position of the glucopyranose units and the concurrent absence of hydroxy groups at the 2-position were evidenced as important factors for enantioseparation of daclatasvir and its enantiomer by methylated β-CDs.

01 Nov 2024·Annales Pharmaceutiques Françaises

Validated LC/MS method for simultaneous determination of elbasvir and grazoprevir in human plasma

Article

Author: Bensghaier, Rafika ; Labidi, Aymen ; Latrous, Latifa ; Jebali, Sami

A sensitive and accurate LC/MS method for the determination of elbasvir (ELB) and grazoprevir (GZP) in human plasma was established using daclatasvir (DCT) as an internal standard. The analytes were separated on a Waters Spherisorb phenyl column (150mm×4.6mm ID, 5μm particle size) maintained at 40°C±2°C. Gradient elution, at a flow rate of 0.8mLmin^-1, was used. The mobile phase consists of 90% of acetonitrile mixed to 10% of a 5mM ammonium formate buffer (+0.1% v/v of trimethylamine, pH was adjusted to 3.2 by formic acid) as phase A and 10% of acetonitrile mixed to 90% of the same buffer as phase B. Liquid-liquid extraction with ethyl acetate solvent was used to recuperate compounds from plasma. The method was validated over a concentration range of 2 and 100ng/mL for GZP and between 1 and 50ng/mL for ELB. The intra- and inter-day precision and accuracy of the quality control samples at low, medium, and high concentration levels exhibited relative standard deviations (RSD)<15%, and the accuracy values ranged from 94.2 to 107.8%. The robustness of the method was established using a two-level full factorial design.

News (Medical) associated with Daclatasvir Dihydrochloride

28 Feb 2023

·www.biospace.com

Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

Dr. Coric currently serves as the Chairman and Chief Executive Officer of Biohaven (BHVN) NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023. Dr. Coric brings more than 22 years of drug development and executive leadership experience to Revance based on his time at the Yale School of Medicine, Bristol-Myers Squibb, and Biohaven, which was acquired by Pfizer in 2022. The company also announced that long-standing director Philip Vickers has decided that he will be retiring from the Board effective immediately prior to the company’s 2023 Annual Meeting of Stockholders. "Vlad’s leadership and proven track record in biotech value creation from discovery to commercialization, particularly in the field of neurology, will further enhance the collective experience and skillset of our diverse Board," said Mark J. Foley, Chief Executive Officer of Revance. “His appointment comes at a dynamic time for Revance as we accelerate our commercial growth in aesthetics and look to advance our significant opportunity in therapeutics. As we welcome Vlad to the Board, I would also like to thank Phil Vickers for his invaluable contributions over the past eight years in guiding the scientific progress at Revance, marked by the approval of DAXXIFY® in glabellar lines and our successful Phase 3 clinical trials for DAXXIFY® in cervical dystonia.” “Revance’s people, strategy and breakthrough innovation in the neuromodulator category uniquely positions the company to disrupt both the aesthetics and therapeutics market,” said Dr. Valid Coric, M.D. “I look forward to working with Mark, the rest of the leadership team and the Board to support Revance’s continued progress and advancement of innovative therapies that have the potential to maximize the benefit of DAXXIFY’s efficacy and long-duration profile.” Dr. Coric is currently the Chairman and CEO of Biohaven, where he has successfully led the approval and commercialization of its Nurtec® ODT and CGRP franchise in addition to the expansion of company’s therapeutic portfolio targeting neurological and neuropsychiatric diseases. He also led Biohaven’s acquisition of its novel Kv7 channel platform and the sale of the Biohaven to Pfizer in October 2022 for total considerations of $13 billion. Previously, Dr. Coric was the Group Director, Neuroscience and Oncology Global Clinical Research, and Medical Director, Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company. He also previously served on the board of directors of Social Capital Suvretta Holdings Corp. I (DNAA) from 2021-2022 and he currently serves on the boards of directors of private biotech companies including Veradermics, Inc., Vita Therapeutics, Inc., and Pyramid Biosciences, Inc. During his career, Dr. Coric has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec® ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor). Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine, has published over 65 peer-reviewed publications and has lectured nationally on neurological and psychiatric disorders. He earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity. Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at , , , or connect with us on LinkedIn. “Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. Forward-Looking Statements Any statements in this press release that are not statements of historical fact, including statements related to our ability to set a new standard in healthcare; our commercial growth; our opportunity in the aesthetics and therapeutics markets; our ability to disrupt the aesthetics and therapeutics markets; the outcomes for and experiences of patients and physicians; the development of innovative therapies; the potential benefits, safety, efficacy and duration of DAXXIFY®; and development of a biosimilar to BOTOX® to compete in the short-acting neuromodulator marketplace; constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: our ability to successfully commercialize DAXXIFY® and to continue to successfully commercialize the RHA® Collection of dermal fillers and OPUL®; the results, timing, costs, and completion of our research and development activities and regulatory approvals; our ability to obtain funding for our operations; the timing of capital expenditures; the accuracy of our estimates regarding future expenses, revenues and capital requirements, our financial performance and the economics of DAXXIFY®, the RHA® Collection of dermal fillers and OPUL®; the impact of the COVID-19 pandemic and other macroeconomic factors on our manufacturing operations, supply chain, end user demand for our products and services, the aesthetics market, commercialization efforts, business operations, regulatory meetings, inspections and approvals, clinical trials and other aspects of our business and on the market; our ability and the ability of our partners to manufacture supplies for DAXXIFY® and our product candidates and to acquire supplies of the RHA® Collection of dermal fillers; the uncertain clinical development process; the risk that clinical trials may not have an effective design or generate positive results or that positive results would assure regulatory approval or commercial success; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, safety, efficacy, commercial acceptance, market, competition and/or size and growth potential of DAXXIFY®, the RHA® Collection of dermal fillers, and our drug product candidates, if approved; the rate and degree of commercial acceptance, market, competition and growth potential of OPUL®; reports of adverse events or safety concerns involving DAXXIFY® or the RHA® Collection of dermal fillers; the timing and cost of commercialization activities; the proper training and administration of our products by physicians and medical staff; our ability to expand sales and marketing capabilities; the status of commercial collaborations; changes in and failures to comply with privacy and data protection laws; our ability to effectively manage our expanded operations in connection with the acquisition of Hint, Inc; our ability to continue obtaining and maintaining intellectual property protection for DAXXIFY® and our drug product candidates; the cost and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; the volatility of our stock price; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risks Factors" on our Form 10-K expected to be filed with the SEC on February 28, 2023. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements. View source version on businesswire.com: Contacts Investors Revance Therapeutics, Inc.: Jessica Serra, 510-279-6886 Jessica.serra@revance.com or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 laurence@gilmartinir.com Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 sfahy@revance.com Source: Revance Therapeutics, Inc. View this news release online at:

Executive ChangePhase 3Acquisition

19 Oct 2022

·www.biospace.com

Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease

BOSTON & NEW YORK--(BUSINESS WIRE)-- Anji Pharmaceuticals and Population Health Partners today announced that they have entered into a strategic collaboration, bringing together two complementary teams to jointly address high prevalence human diseases. Anji Pharmaceuticals (‘Anji’) is an emerging global medicines company founded by CEO Dr. Brian Hubbard, who has led therapeutics discovery and development programs at the Broad Institute of MIT and Harvard, Merck, Novartis, and Millennium Pharmaceuticals. Anji co-founders also include CMO Dr. Dan Meyers, who has designed and led over 40 clinical trials; CSO Dr. Mike Serrano-Wu, who was part of discovery teams that identified daclatasvir, pradigastat, and 5 additional molecules which have reached clinical trials; and COO Dr. Yiwei Zong, an experienced investor and entrepreneur. Anji is progressing high potential late-stage clinical assets in Phase II and Phase III development. Population Health Partners (‘PHP’) is a global life-science investment firm founded by Dr. Clive Meanwell, who has led therapeutics development programs in his roles as Founder and CEO of The Medicines Company, and in a range of executive positions at Roche. Other Partners at PHP include Ian Read, former Chairman and CEO of Pfizer; Dr. Roy Berggren, former lead of McKinsey’s global Life Sciences practice; and Chris Cox, former head of Cadwalader Wickersham and Taft’s global corporate law practice. PHP will work with Anji to support their portfolio and to advise on strategic and operational matters as they advance clinical assets which have high potential to improve the lives and reduce the health burdens on millions of people with prevalent diseases and/or disease risk factors. “We’ve built Anji to be an agile asset-centric biopharma enterprise that can repeatedly unlock value of clinical programs where we see high validation and unmet need,” said Brian Hubbard, Ph.D., co-founder and CEO of Anji. “Teaming up with PHP is clearly one of those ‘1+1 = 3’ moments, where the deep skillsets of each will equip Anji to deliver life-changing medicines to patients even more quickly.” The initial focus of the Anji/PHP collaboration is to accelerate development of the two lead clinical assets in Anji’s pipeline. ANJ900 (delayed-release metformin) is an investigational agent currently in Phase 3 trials to enable safe use of metformin in Type 2 diabetes patients with advanced chronic kidney disease (CKD). Previous trials with ANJ900 demonstrated clinically meaningful glucose lowering with only one-third the plasma concentrations observed with currently marketed formulations of metformin. This finding points to the potential for expanded and improved treatment for CKD patients in whom metformin use is currently contraindicated. ANJ908 (pradigastat) is a novel DGAT1 inhibitor which has completed a successful Phase 2 study in patients with chronic idiopathic constipation (NCT04620161). This proof-of-concept study was performed across 25 clinical trial sites in U.S. and China and demonstrated the potential efficacy, safety, and dose range of pradigastat in patients who met the Rome IV criteria for constipation. Chronic idiopathic constipation affects nearly one in seven Americans, with nearly two million patients seeking pharmacotherapy options worldwide. Anji anticipates sharing preliminary results from the study later this year. “Anji has an extraordinary team – and an inspiring proven leader in Brian. Their ability to unpack the complexities of biology, chemistry, pharmacology, and clinical performance so that they can recognize high potential value and perform efficient drug development programs is highly impressive,” said Clive Meanwell, M.D., Chairman and Managing Partner of PHP. “We will put PHP’s knowledge and experience to work in order to help Anji create value, and produce a positive impact on prevalent diseases.” Locust Walk serves as an advisor to Anji and will work in concert with Anji and PHP to further the goals of the strategic collaboration. About Anji Pharma Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients across the globe. Anji’s asset-centric business model allows for speed and flexibility in building value, leveraging a clinical and regulatory core that operates with “hub-and-spoke" efficiency. Anji has R&D expertise in Boston, Shanghai, and Berlin, and is preparing additional programs for early clinical development. For more info, visit . About Population Health Partners, L.P. Population Health Partners, L.P. is a private equity firm committed to building great companies around important late-stage therapeutics and solving the health and economic challenges presented by prevalent diseases. While at The Medicines Company, leaders from Population Health Partners secured eight drug approvals involving 21 clinical trials and 91,000 randomized patients and were ranked #1 in the CNBC RQ 50 for biopharmaceutical R&D productivity. For more info, visit .

28 Jan 2016

·www.pharmatimes.com

EU expands use of BMS' hepatitis drug Daklinza

Bristol-Myers Squibb’s Daklinza has been cleared in Europe for the treatment of chronic hepatitis C in three new difficult-to-treat patient populations. The drug’s expanded label now includes use of the drug in combination with sofosbuvir (Gilead’s Sovaldi, with or without ribavirin) in hepatitis C (HCV) patients with decompensated cirrhosis, HIV-1 co-infection, and post-liver transplant recurrence. Daklinza (daclatasvir) is already approved in Europe for use in combination with other therapies across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection in adults, and the Daklinza/sofosbuvir regimen is the only approved 12-week, all-oral treatment for genotype 3 HCV patients without cirrhosis. The new indications are based on data from the Phase III ALLY clinical trials, which showed high sustained virologic response (SVR) rates across the patient subsets. In ALLY-2, the Daklinza/sofosbuvir regimen demonstrated overall SVR12 in 97% of patients co-infected with HIV, including 100% in genotype 3, and SVR12 rates were found to be greater than 94% across all combination antiretroviral therapy regimens, BMS said. In ALLY-1, 94% of post liver-transplant patients and 83% of patients in the cirrhosis cohort achieved SVR12. The drug’s expanded approval “is an important step forward for a significant group of patients with chronic hepatitis C who are still in need of treatment options that can deliver high cure rates,” noted Douglas Manion, head of Specialty Development, BMS. “The complex clinical considerations for physicians treating HCV/HIV coinfected patients and patients with cirrhosis, decompensated cirrhosis or post-transplant recurrence of HCV reinforces the vast diversity of this disease, and we have worked hard to continue to identify and address those patients who require additional solutions for cure.”

100 Deals associated with Daclatasvir Dihydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10105	Daclatasvir Dihydrochloride	J05AP07	DB09102

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis C	CN	Bristol-Myers Squibb (Singapore) Pte Ltd.	24 Apr 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C, Chronic	Phase 1	LI	Bristol-Myers Squibb Pharma EEIG	22 Aug 2014
Hepatitis C, Chronic	Phase 1	NO	Bristol-Myers Squibb Pharma EEIG	22 Aug 2014
Hepatitis C, Chronic	Preclinical	NO	Bristol-Myers Squibb Pharma EEIG	22 Aug 2014
Hepatitis C, Chronic	Preclinical	LI	Bristol-Myers Squibb Pharma EEIG	22 Aug 2014
Hepatitis C, Chronic	Preclinical	EU	Bristol-Myers Squibb Pharma EEIG	22 Aug 2014
Hepatitis C, Chronic	Discovery	EU	Bristol-Myers Squibb Pharma EEIG	22 Aug 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01866930 (DIMENSION, CTgov)	Phase 3	Coinfection \| HIV Infections \| Hepatitis C, Chronic	453	Lambda+DCV+Ribavirin+RBV (Cohort A: HCV GT-2 or GT-3)	kstounswjz(oylaycvlvw) = cmmswctpup mwdqptelpv (fdsgimdqxk, jnhxduttqh - cuspbsnlib) View more	-	13 Jun 2023
				Lambda+DCV+Ribavirin+RBV (Cohort B: HCV GT-1 or GT-4)	kstounswjz(oylaycvlvw) = vbdnoobabq mwdqptelpv (fdsgimdqxk, fkuuhwudtz - getlebsbkf) View more
ISN WCN2023	Not Applicable	-	125	Sofosbuvir 200 mg	wiqlpqwafn(anncfqhjqu) = No patient discontinued antiviral therapy due to side effects fpuvhqbaup (beauxalbkv ) View more	Positive	01 Mar 2023
				Daclatasvir 60 mg
NCT04070235 (Pubmed \| J Viral Hepat)	Phase 2	Hepatitis C	124	Daclatasvir 60 mg + Alfosbuvir 400 mg	(lafdwkhxjf) = glnsxluygh zkvzeflxeg (ptyjdlkyyy )	Positive	26 Jan 2022
				Daclatasvir 60 mg + Alfosbuvir 600 mg	(lafdwkhxjf) = wjflvttlki zkvzeflxeg (ptyjdlkyyy )
SH229 (EASL2021)	Phase 3	Hepatitis C, Chronic	327	SH229 plus daclatasvir	qbtjmnjyld(ewdjsrbkih) = obvdmufgjr ztgjxijhec (tdixsmdeca, 96.5% - 99.5%)	Positive	23 Jun 2021
NCT03480932 (CTgov)	Phase 2/3	Hepatitis C, Chronic	150	Sofosbuvir+Pegylated interferon alfa-2a+Daclatasvir (SOF+DAC+PEG)	uxrfvtdyxc(yknitcghky) = anofaahyim hczrwrzuow (mqncyxfnkf, qstcvpjfpq - udrdpatyrd) View more	-	18 May 2021
				Sofosbuvir+Daclatasvir (SOF+DAC, DOT)	uxrfvtdyxc(yknitcghky) = fakkvvrcyu hczrwrzuow (mqncyxfnkf, pjhpgpbluu - dquchfpvkc) View more
SH229 plus daclatasvir (EASL2020)	Phase 2	Hepatitis C, Chronic	124	SH229 400 mg + Daclatasvir 60 mg	hyfchlgihc(imrkxybvak) = wfmnmcrtab txvbnvcvoo (hjjsividke ) View more	Positive	27 Aug 2020
				SH229 600 mg + Daclatasvir 60 mg	hyfchlgihc(imrkxybvak) = zbqqwfddtr txvbnvcvoo (hjjsividke ) View more
EASL2020	Phase 2	Hepatitis C	10	AT-527 550 mg + Daclatasvir 60 mg	vipmqfkfvq(frhhocgiav) = ucdiqidbcn pecafyjrca (kxwflsygdl ) View more	Positive	27 Aug 2020
NCT03200184 (SD1000, Pubmed \| Clin Infect Dis) Manual	Phase 3	Hepatitis C	1,361	Sofosbuvir and daclatasvir (intention-to-treat)	(dtznzdvrqn) = owmsjsanfh opgvfmsgag (grhsxeqaop )	Positive	06 May 2020
				Sofosbuvir and daclatasvir (per-protocol)	(dtznzdvrqn) = mjfhfdrejs opgvfmsgag (grhsxeqaop )
NCT03540212 (Pubmed \| Curr Opin Pulm Med)	Phase 2/3	Hepatitis C	17	Daclatasvir 60 mg	(uchakcddve) = juegwhixro fktzcxdwoc (qgkyquncen ) View more	-	05 May 2020
ISN WCN2020	Not Applicable	Maintenance	82	Half-dose Sofosbuvir [200 mg] and Daclatasvir (60 mg)	zhhtwcbmlw(raecpdoswu) = There were nonsignificant gastrointestinal side effects in the full dose Sofosbuvir group. All patients tolerated the DAAs well and none of the patients reported any serious adverse events. No patient discontinued antiviral therapy due to side effects uqjujvqerf (gkasqdctqv ) View more	Positive	01 Mar 2020
				Full-dose Sofosbuvir 400mg and Velpatasvir (100 mg)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis